TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02204670

Intervention type: OTHER
Intervention: Acute release of irisin after a single exercise session.
Description: We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
Study: NCT03053882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mouthwash
Description: mouthwash containing herbal peppermint or green tea
Study: NCT00721409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study: NCT01367275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: 800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
Study: NCT03405207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 50000 UNT Oral Capsule
Description: Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
Study: NCT02165813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
Study: NCT03825588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASAP (As Safe As Possible)
Description: ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASAP (As Safe As Possible)
Description: ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITE smart phone app
Description: BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITE smart phone app
Description: BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
Study: NCT02713178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study: NCT01350817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + docetaxel
Description: docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel :75 mg/m² IV day 1 every 3 weeks.
Study: NCT04288934

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collection and expansion of BM-MSC
Description: MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collection and expansion of BM-MSC
Description: MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VI-SCI evaluation and patients' follow up
Description: * At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VI-SCI evaluation and patients' follow up
Description: * At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection.
Study: NCT01082744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Sufentanil
Description: Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
Study: NCT02165813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
Study: NCT02760875

Intervention type: BEHAVIORAL
Intervention: Early weight bearing
Description: The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
Study: NCT03405207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: identical as active drug providing by pharmaceutical company unless it is placebo
Study: NCT00567203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3463275
Description: PF-3463275 10mg
Study: NCT04041570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO S vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO S vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
Study: NCT04866966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared medical appointments for weight loss
Description: Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
Study: NCT03640169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health management of TCM preventive medicine
Description: The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
Study: NCT01180244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive cortical electrical stimulation
Description: Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham treatment
Description: Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
Study: NCT03150836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
Study: NCT04190355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigant type
Description: The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
Study: NCT03150836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
Study: NCT04190355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% NaOCl
Description: 5.25% NaOCl solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% Cloraxid gel/ distilled water
Description: 5.25% Cloraxid gel/ distilled water
Study: NCT00870454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300 mg/d
Description: 75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/d
Description: 200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg/d
Description: 200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily
Study: NCT00914407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% Oxygen inhalation for 30 minutes
Study: NCT03150836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
Study: NCT00849563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Risk Assessment
Description: patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
Study: NCT00567203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3463275
Description: PF-3463275 25mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02304705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg three times daily by mouth for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule three times daily by mouth for 90 days
Study: NCT02675647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, IV route, based on patients body weights (UI/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, IV route, based on patients body weights (UI/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protamin administration
Study: NCT04136821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Study: NCT03891771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring sensors
Description: This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
Study: NCT00736268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based Enhanced Coping Skills Training (CST)
Description: Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Medical Care and COPD education and symptom monitoring (UMC)
Description: COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
Study: NCT04410601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
Study: NCT03275597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
Study: NCT03714698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise group
Description: Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
Study: NCT01367288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa + Neoadjuvant therapy
Description: 4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
Study: NCT01015040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate suspension
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate suspension
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate tablet
Description: Oral
Study: NCT04415320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396(Ensartinib)
Description: All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
Study: NCT00559312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol combination
Description: Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Diskus inhaler, twice daily, 6-week duration
Study: NCT00954187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 50 mg PO TID
Study: NCT01242579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc/Dapivirine Gel
Description: Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Gel
Description: Dapivirine vaginal gel containing 2.5g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc Vaginal Gel
Description: Maraviroc vaginal gel containing 2.5g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Gel
Description: Matching placebo gel containing 2.5g
Study: NCT02914340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Study: NCT00316602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: Subjects receiving two subcutaneous vaccinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: Subjects receiving two subcutaneous vaccinations